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Regarding the continuous changes in the diagnostic process and treatment of colorectal cancer (CRC), it is important to evaluate
long-term trends which are relevant in giving direction for further research and innovations in cancer patient care. The aim of this
study was to analyze developments in incidence, treatment and survival for patients diagnosed with CRC in the Netherlands. For
this population-based retrospective cohort study, all patients diagnosed with CRC between 1989 and 2014 in the Netherlands
were identiﬁed using data of the nationwide population-based Netherlands Cancer Registry (n = 267,765), with follow-up until
January 1, 2016. Analyses were performed for trends in incidence, mortality, stage distribution, treatment and relative survival
measured from the time of diagnosis. The incidence of both colon and rectal cancer has risen. The use of postoperative
chemotherapy for Stage III colon cancer increased (14–60%), as well as the use of preoperative (chemo)radiotherapy for rectal
cancer (2–66%). The administration of systemic therapy and metastasectomy increased for Stage IV disease patients. The 5-year
relative survival increased signiﬁcantly from 53 to 62% for colon cancer and from 51 to 65% for rectal cancer. Ongoing
advancements in treatment, and also improvement in other factors in the care of CRC patients—such as diagnostics, dedicated
surgery and pre- and postoperative care—lead to a continuous improvement in the relative survival of CRC patients. The increasing
incidence of CRC favors the implementation of the screening program, of which the effects should be monitored closely.
Introduction
Colorectal cancer (CRC) is one of the most common cancer
types in developed countries, with more than 15,000 newly
diagnosed patients in the Netherlands in 2016.1,2 The epide-
miology and treatment of CRC have seen major changes over
the years.3 The incidence of CRC in the Dutch population has
increased over time and although mortality rates have
decreased, CRC is still the second leading cause of cancer-
related death, accounting for over 4,900 deaths in 2014.1 To
further decrease mortality rates, the Dutch government intro-
duced a nationwide screening program for CRC in 2014.4
Survival rates of CRC patients in the Netherlands have been
improving since the end of the 1980s, which has been attrib-
uted to major advancements in the diagnostic process and
treatment of CRC, ensuring that a successful multimodality
management of CRC requires a multidisciplinary approach. CT
scanning has become standard for staging with the addition of
MRI in rectal cancer patients.5 Improved surgical techniques as
well as subspecialization substantially contributed to the quality
of oncological treatment, besides reducing morbidity.6–8 Preop-
erative radiotherapy options have increased with several new
schedules combining this modality with systemic treatment as
induction, concomitant or consolidation therapy.9,10 The use of
postoperative 5-ﬂuorouracil-based chemotherapy has become
standard treatment in high-risk Stage II and Stage III colon
cancer patients.11,12 For metastatic CRC, the use of combina-
tion chemotherapy, various new systemic and regional multi-
modality treatments, metastasectomies and other local
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treatments, such as hyperthermic intraperitoneal chemotherapy,
are increasingly being performed.13–15
Regarding the continuous changes in the diagnostic pro-
cess and treatment of CRC, it is important to evaluate both
long-term trends and trends during the most recent years,
which are relevant to give direction for further research and
innovations in cancer patient care. Therefore, the aim of this
study was to analyze trends in incidence, mortality, stage dis-
tribution, treatment and relative survival for patients diag-
nosed with CRC between 1989 and 2014 in the Netherlands.
Methods
Data collection
Nationwide population-based data on CRC patients from
1989 onward were obtained from the Netherlands Cancer
Registry (NCR). Since 1989, the NCR registers all newly diag-
nosed malignancies in the Netherlands. The NCR mainly
receives notiﬁcation from the pathology departments of hospi-
tals, all taking part in the automated pathology archive
(PALGA), and the National Registry of Hospital Discharge
Diagnoses (LMR). Following the notiﬁcation, trained data
managers gather patient, tumor and treatment characteristics
directly from the medical records.
Anatomical subsite of the tumor is coded according to
International Classiﬁcation of Diseases for Oncology (ICD-
O).16 The tumor-node-metastasis (TNM) classiﬁcation was
used for stage notiﬁcation of the primary tumor, according to
the edition valid at time of cancer diagnosis.17 As clinical
nodal staging of CRC is rather unreliable with a sensitivity of
only 41% and speciﬁcity of 84% in daily practice,18 pathologi-
cal TNM took precedence over clinical stage except in case of
unknown pathological stage. In case of a positive cM, stage
was always registered as Stage IV. Patients with CRC Stage
0 were patients with a pathological complete response after
preoperative treatment.
All cases of primary CRC diagnosed in the period
1989–2014 were selected for this study. The study period was
divided into ﬁve time periods of 5 years each (1989–1994,
1995–1999, 2000–2004, 2005–2009 and 2010–2014). Patients
were stratiﬁed by tumor localization: colon (C18) and rectum
(rectosigmoid and rectum, C19–C20).
Patients’ vital status was obtained by linking the NCR to
the Municipal Personal Records Database. Follow-up was
completed until January 1, 2016.
Statistical analyses
For analyses on patient and tumor characteristics, incidence and
mortality, data from all patients were included. The χ2 test was
used to analyze differences in patient and tumor characteristics.
Annual incidence and mortality were described per 100,000
person-years and standardized according to the European Stan-
dard Population,19 resulting in the European Standardized Rates
(ESR). In addition, analyses of trends in incidence and mortality
were achieved by an average annual percentage of change analysis.
For the analyses on treatment and survival, patients with
either no histologically conﬁrmed CRC or unknown TNM-
stage were excluded. For metachronous primary tumors, the
ﬁrst diagnosed CRC was included. In case of synchronous
multiple CRC, the tumor with the most advanced TNM-stage
was used. Treatment characteristics were reported as percent-
ages per age group and per time period.
Age-standardized relative survival was calculated for the dif-
ferent age groups as the ratio of the survival observed among
the CRC patients to the survival that would have been expected
based on age, gender and year of the corresponding general
population (Pohar Perme method).20 The relative survival ana-
lyses were performed according to tumor localization and stage.
p values <0.05 were considered statistically signiﬁcant.
Analyses were performed in SAS/STAT® statistical software
(SAS system 9.4, SAS Institute, Cary, NC), STATA (version
13.0, Statcorp LP, College Station, TX) and SPSS Statistics for
Windows (version 22.0, IBM Corp, Armonk, NY).
Results
Between 1989 and 2014, 267,765 patients were diagnosed with
CRC in the Netherlands.
Patient and tumor characteristics are presented in Table 1.
There was an increase over time in the proportion of colon
tumors compared with rectal tumors. The proportion of males
has increased in both colon and rectal cancer. The propor-
tional stage distribution shows a decrease in Stage II, whereas
the proportion of Stage IV increased. Moreover, a recent trend
is the increasing number of rectal cancer patients with a com-
plete pathological response (Stage 0) after preoperative treat-
ment, starting from the period 2005–2009.
Incidence and mortality (European standardized rates)
The incidence of CRC in the Netherlands increased by 35% in
the last 25 years. Figure 1a illustrates an increase in age stan-
dardized incidence, more pronounced for males, and decrease
What’s new?
To best inform new directions for cancer management, it’s important to study historical trends. Here, the authors analyzed
25 years of data in The Netherlands on colorectal cancer incidence, treatment and survival. During the period from 1989 to
2014, both incidence and 5-year relative survival increased. Certain treatments also became more common, such as
postoperative chemotherapy for Stage III patients and systemic therapy and surgical removal of metastases for Stage IV
patients. Improved diagnostics and treatments have helped more patients survive, and the rising incidence of CRC supports
the use of the nationwide screening program, introduced by the Dutch government in 2014.
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Table 1. Tumor site distribution of all patients diagnosed with colorectal cancer, and age, gender, morphology and TNM-stage distribution of
all patients diagnosed with colon or rectal cancer in the Netherlands between 1989 and 2014, by period of diagnosis
Period of diagnosis
1989–1994 (%) 1995–1999 (%) 2000–2004 (%) 2005–2009 (%) 2010–2014 (%)
CRC
Tumor site
Colon 30,136 (66) 28,417 (65) 32,486 (65) 40,140 (67) 47,674 (69)
Rectum 15,812 (34) 14,973 (35) 17,114 (35) 19,741 (33) 21,272 (31)
Colon
Age at diagnosis
0–49 1,885 (6) 1,583 (6) 1,714 (5) 1,826 (5) 2,047 (4)
50–59 3,418 (11) 3,432 (12) 4,195 (13) 4,878 (12) 5,008 (11)
60–69 7,668 (25) 6,989 (25) 7,793 (24) 10,025 (25) 13,135 (28)
70–79 10,330 (34) 9,935 (35) 11,381 (35) 13,467 (34) 16,254 (34)
80+ 6,835 (23) 6,478 (23) 7,403 (23) 9,944 (25) 11,230 (24)
Gender
Male 13,916 (46) 13,720 (48) 15,938 (49) 20,369 (51) 25,054 (53)
Female 16,220 (54) 14,697 (52) 16,548 (51) 19,771 (49) 22,620 (47)
Morphology
Adenocarcinoma 22,994 (76) 22,195 (78) 25,945 (80) 32,455 (81) 40,015 (84)
Mucinous adenocarcinoma 5,739 (19) 4,908 (17) 5,141 (16) 5,736 (14) 5,305 (11)
Signet ring cell carcinoma 287 (1) 314 (1) 375 (1) 571 (1) 650 (1)
Other 1,116 (4) 1,000 (4) 1,025 (3) 1,378 (3) 1,704 (4)
TNM-stage
Stage I1 4,674 (16) 4,291 (15) 4,772 (15) 6,286 (16) 8,770 (18)
Stage II 11,267 (37) 10,209 (36) 11,311 (35) 12,579 (31) 13,850 (29)
Stage III 6,637 (22) 6,778 (24) 7,895 (24) 10,001 (25) 11,972 (25)
Stage IV 5,833 (19) 5,433 (19) 6,691 (21) 8,861 (22) 11,211 (24)
Stage X 1,725 (6) 1,706 (6) 1,817 (6) 2,413 (6) 1,871 (4)
Rectum
Age
0–49 1,173 (7) 1,030 (7) 1,125 (7) 1,274 (6) 1,315 (6)
50–59 2,278 (14) 2,425 (16) 3,085 (18) 3,430 (17) 3,319 (16)
60–69 4,403 (28) 4,101 (27) 4,838 (28) 5,787 (29) 6,740 (32)
70–79 4,974 (31) 4,718 (32) 5,135 (30) 5,906 (30) 6,391 (30)
80+ 2,984 (19) 2,699 (18) 2,931 (17) 3,344 (17) 3,507 (16)
Gender
Male 8,763 (55) 8,555 (57) 9,970 (58) 11,674 (59) 13,116 (62)
Female 7,049 (45) 6,418 (43) 7,144 (42) 8,067 (41) 8,156 (38)
Morphology
Adenocarcinoma 13,768 (87) 13,189 (88) 15,115 (88) 17,701 (90) 19,578 (92)
Mucinous adenocarcinoma 1,630 (10) 1,431 (10) 1,550 (9) 1,516 (8) 1,188 (6)
Signet ring cell carcinoma 287 (1) 314 (1) 375 (1) 571 (1) 650 (1)
Other 330 (2) 258 (2) 348 (2) 370 (2) 374 (2)
TNM-stage
Stage 0 1 (0) 3 (0) 26 (0) 435 (2) 1,017 (5)
Stage I 4,175 (26) 3,845 (26) 4,402 (26) 5,097 (26) 6,076 (29)
Stage II 4,344 (27) 3,837 (26) 4,309 (25) 4,427 (22) 4,106 (19)
(Continues)
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in mortality for colon cancer patients. The same trends in
incidence and mortality as for colon cancer patients can be
seen for rectal cancer patients, although they are less obvious
(Fig. 1b). For all groups, a strong increase in incidence is seen
in 2014 following the introduction of the national screening
program.
Treatment
In Table 2, trends in treatment for colon and rectal cancer are
presented. Almost all patients diagnosed with Stages I–III
colon cancer underwent resection (including local excisions).
Administration of postoperative systemic therapy increased in
patients with Stages II and III colon cancer. In patients
Table 1. (Continued)
Period of diagnosis
1989–1994 (%) 1995–1999 (%) 2000–2004 (%) 2005–2009 (%) 2010–2014 (%)
Stage III 3,573 (23) 3,614 (24) 4,278 (25) 4,945 (25) 5,214 (25)
Stage IV 2,436 (15) 2,427 (16) 3,078 (18) 3,901 (20) 4,236 (20)
Stage X 1,283 (8) 1,247 (8) 1,021 (6) 936 (5) 623 (3)
Data are absolute numbers with percentages between parentheses.
10.2% of these patients were Stage pT0, the majority of the pT0 patients were colon sigmoideum patients of which 51% had neo-adjuvant treatment.
Note.  
Estimated average annual percentage of change 
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Figure 1. European age standardized (ESR) incidence and mortality rates per 100,000 person-years, according to gender and tumor site.
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diagnosed with Stage IV colon cancer, the combination of sys-
temic therapy and resection, the use of only systematic ther-
apy and the use of metastasectomy increased.
The primary tumor in nonmetastasized rectal cancer was
almost always resected. The use of preoperative radiotherapy
and chemoradiotherapy increased over time. The administra-
tion of postoperative chemotherapy increased until 2005–2009
in patients with Stage II/III rectal cancer, but decreased in
more recent years. In patients with Stage IV rectal cancer,
similar trends can be seen as for colon cancer.
Survival
Relative survival is depicted in Figure 2 and has improved
over time for both colon and rectal cancer. For patients with
Stage I colon cancer, the relative survival remained stable over
time. Relative survival improved during all periods for
patients with Stages II or III colon cancer, being most pro-
nounced increase in the latter with an improvement in 5-year
survival from 45 to 68%. The 5-year survival for patients with
Stage IV colon cancer increased from 4 to 12%.
Also for patients with Stages I or II rectal cancer, an
improvement in survival can be seen. For patients with Stage
III rectal cancer, no further increase was observed in 5-year
survival in 2010–2014. The improvement in survival for
patients with Stage IV rectal cancer was similar to the
improvement in survival for Stage IV colon cancer. The 5-year
survival increased for all colon cancer stages combined from
53 to 62%, and for all rectal cancer stages combined from
51 to 65%.
Discussion
This large population-based study provides an overview of the
vast changes in incidence, mortality, treatment and survival of
CRC in the Netherlands in the period 1989–2014. Changes in
treatment were seen next to a signiﬁcant increase in overall as
well as stage-speciﬁc relative survival for both colon and rectal
cancer patients. Furthermore, intensiﬁed treatment of Stage
IV CRC has also resulted in better outcome for metastasized
patients with a generally poor prognosis.
The incidence of CRC in the Netherlands increased by
35% in the last 25 years. The implementation of a nationwide
bowel screening program in the Netherlands explains the
steep increase in the incidence of both colon and rectal cancer
in 2014, which is expected to continue for several years.21 The
annual CRC mortality in the Netherlands has decreased mod-
estly over the years, and is expected to decrease further
because of the screening program, resulting in earlier diagno-
sis and thereby more curative treatment options.22 The trend
of increasing incidence and decreasing mortality of CRC
patients is in line with trends in other Western countries
Table 2. Trends in primary treatment for patients with colon or rectal cancer in the Netherlands, according to postoperative stage
Period of diagnosis
Treatment Stage
1989–1994
(%)
1995–1999
(%)
2000–2004
(%)
2005–2009
(%)
2010–2014
(%)
Colon
Resection I–III 21,389 (98) 19,952 (99) 22,333 (98) 26,653 (98) 31,693 (98)
Postoperative chemotherapy II 251 (2) 297 (3) 438 (4) 877 (7) 1,024 (8)
III 918 (14) 2,465 (38) 4,019 (53) 5,621 (58) 6,855 (60)
Resection of primary tumor only IV 3,341 (59) 2,624 (50) 2,295 (35) 2,097 (24) 1,812 (17)
Use of systemic therapy only IV 299 (5) 384 (7) 889 (14) 1,947 (23) 3,112 (30)
Both resection of the primary
tumor and systemic therapy
IV 671 (12) 1,061 (20) 1,841 (28) 2,779 (32) 3,471 (33)
Metastasectomy IV 104 (2) 264 (5) 391 (6) 915 (11) 1,810 (17)
Rectum
Resection 0–III 11,439 (96) 10,593 (96) 12,141 (95) 13,774 (95) 14,581 (92)
Preoperative radiotherapy 0–III 196 (2) 1,590 (14) 5,634 (44) 6,552 (45) 5,578 (35)
Preoperative chemoradiation 0–III 11 (0) 88 (1) 391 (3) 2,751 (19) 4,964 (31)
Postoperative radiotherapy II/III 2,315 (30) 1,218 (17) 478 (6) 225 (2) 163 (2)
Postoperative chemotherapy II/III 295 (4) 688 (9) 1,142 (14) 1,495 (16) 899 (10)
Resection of primary tumor only IV 1,192 (49) 958 (40) 776 (26) 556 (15) 434 (11)
Use of systemic therapy only IV 149 (6) 226 (9) 593 (20) 1,377 (36) 1,778 (43)
Both resection of the primary
tumor and systemic therapy
IV 236 (10) 418 (18) 748 (25) 936 (24) 833 (20)
Metastasectomy IV 54 (2) 127 (5) 212 (7) 550 (14) 939 (23)
Data are presented as absolute numbers with percentages of patients who underwent the respective treatment between parentheses.
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(e.g., Canada, Sweden and the United Kingdom). The rising
incidence rates may be accounted for by major risk factors
such as lifestyle, obesity and dietary habits.23 Interestingly, the
incidence of CRC patients has been declining in other West-
ern countries such as the US, France and Australia. Even
though this difference is often attributed to the adoption of a
western lifestyle and the long-term effects of screening for
CRC, no concluding explanation exists.23,24 In the United
States, a rise in younger individuals being diagnosed with
CRC has been shown, whereas the total incidence of CRC is
declining.24 Data from this study show that in the Nether-
lands, there is no such opposite trend but a rise in the inci-
dence of CRC incidence in both younger and elderly patients.
The increasing incidence and decreasing annual CRC mor-
tality points toward an improvement in survival of CRC
patients, which has been attributed previously to advance-
ments in treatment.3 Results from this study show that re-
section is the cornerstone in the treatment of nonmetastatic
CRC, and the introduction of screening programs will increase
the use of less-invasive procedures such as polypectomies and
local excisions.
Since the 1990s, the use of postoperative systemic therapy
is recommended for Stage III colon cancer, and the adminis-
tration has continued to increase during more recent time
periods.25,26 Considering Stage II colon cancer, Dutch,
European and American guidelines recommend the use of
postoperative chemotherapy only in high-risk patients.12,27
Unfortunately, it was not possible to select for high-risk Stage
II in the NCR database, but a previous Dutch study found that
only 16% of high-risk Stage II patients received postoperative
chemotherapy in 2008–2012.12 Following the Dutch guide-
lines, Stage III and high-risk Stage II patients postoperatively
receive a combination chemotherapy of ﬂuoropyrimidine and
oxaliplatin.
Compared with colon cancer, rectal cancer treatment chan-
ged signiﬁcantly over recent decades. Since 2001, the total
mesorectal excision technique became the standard for rectal
cancer surgery in the Netherlands and contributed to an
improved survival.7,28 Simultaneously, preoperative (chemo)
radiotherapy was implemented in the treatment for Stage
II/III rectal cancer in the Netherlands.7 The addition of preop-
erative (chemo)radiotherapy has not demonstrated an overall
Figure 2. Stage-speciﬁc relative survival and relative survival for all stages combined for colon and rectal cancer, according to postoperative
stage. (a) Relative survival among patients with postoperative Stage I colon cancer (including postoperative Stage 0). (b) Relative survival
among patients with postoperative Stage II colon cancer. (c) Relative survival among patients with postoperative Stage III colon cancer. (d)
Relative survival among patients with postoperative Stage IV colon cancer. (e) Relative survival among patients with postoperative Stage I
rectal cancer (including postoperative Stage 0). (f ) Relative survival among patients with postoperative Stage II rectal cancer. (g) Relative
survival among patients with postoperative Stage III rectal cancer. (h) Relative survival among patients with postoperative Stage IV rectal
cancer. (i) Relative survival among patients with colon cancer, all postoperative stages and ages. ( j) Relative survival among patients with
rectal cancer, all postoperative stages and ages.
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survival beneﬁt in randomized trials, although a more tailored
application for high-risk groups might impact survival based
on subgroup analysis.29
The ﬁndings for metastasized CRC show a continuation of
the trends in treatment described previously in the Dutch
population, with a shift from resection of the primary tumor
alone to either systemic therapy alone or in combination with
surgery of the primary tumor, and an increase in the use of
metastasectomy.3,13 The exact type of received chemotherapy
is not registered in the NCR database, but the Dutch guide-
lines recommend ﬂuoropyrimidine monotherapy for patients
who are likely to receive multiple-line therapy, or combination
chemotherapy (i.e., ﬂuoropyrimidine and oxaliplatin) for
patients who are not. Previous Dutch studies have shown that
combination chemotherapy is not superior to sequential
therapy in Stage IV CRC patients, and that both combination
and sequential treatment regimens are prescribed in daily
practice in the Netherlands, which is in line with current
guidelines.30
The increase in 5-year survival in the more recent periods
seems remarkable as there have been no major changes in
treatment and most of the trends in treatment have leveled off
for localized disease, except for the use of preoperative che-
moradiation. The treatment of metastases has developed fur-
ther over time with the use of metastasectomy and evolved
systemic therapy regimens. However, the minority of patients
with metastasized disease can be treated with curative intent
by metastasectomy, and these treated patients have a 5-year
survival of ~50%.31,32 Systemic therapy in Stage IV CRC yields
a 5-year survival of <10%,32 and of all Stages I–III CRC
Figure 2. (Continued)
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patients, only ~10–30% will develop metastases.33 Therefore,
the potential inﬂuence of these systemic treatment options on
5-year survival is considered to be small.
Besides developing treatment strategies, other mechanisms
might play a role in the increasing survival rates. First, the
gain in 1-year survival in this study suggests a substantial
improvement in the management of factors associated with
short-term mortality, by means of better pre- and postopera-
tive care, and dedicated surgery.34,35 Second, improvement of
diagnostic imaging tools may have led to stage migration due
to detection of small lymph nodes and distal metastases which
were previously missed (the Will Rogers phenomenon). Third,
preoperative chemoradiotherapy in rectal cancer might have
shifted stage-speciﬁc outcome, as postoperative stage has been
used in this study. Patients who respond well to preoperative
treatment have been downstaged, thereby deteriorating sur-
vival rates in the higher stages. This might explain the stagna-
tion in survival improvement of Stage III rectal cancer in
2010–2014. Besides the effect of downstaging, this stagnation
in survival in 2010–2014, relative to the major gains in
2000–2004 and 2005–2009, could also be explained by the
nationwide implementation of TME-surgery in those earlier
periods.28 Last, the improvement in survival in the more
recent years could also be caused by lead-time bias due to ear-
lier diagnosis through various regional screening programs.36
Importantly, survival of all stages combined still improved,
showing that the increase of survival in the present data is not
only the result of stage migration.
Another interesting ﬁnding is that over time, rectal cancer
survival has caught up with colon cancer survival and even
surpassed the latter in the more recent periods of the study.
This has previously been described, and results of this study
show a progression of this trend.3,37
Even though there are persistent differences in relative sur-
vival of CRC across Europe, similar increases in relative sur-
vival were observed for both colon and rectal cancer across
different regions. Compared to other regions in Europe, West-
ern Europe (including the Netherlands) has superior survival
rates for CRC patients, with only slight differences in survival
between countries in this region.38 It is plausible that the
trends described in this study are also applicable to other
West-European countries. Overarching European guidelines
are increasingly incorporated into national guidelines, with an
increase toward multinational collaborative research with
rapid implementation of gained knowledge and new treatment
strategies.
High-quality, long-term nationwide population-based data
were used for this study, making it possible to describe trends
in recent years in the context of long-term trends. However,
there are also some limitations to this study. Comorbidity,
socioeconomic status and ethnicity were missing, which might
have inﬂuenced survival in CRC patients. Also, we decided to
use postoperative stage for our analyses, encountering a
dilemma because treatment strategies are based on clinical
stage. Also, downstaging may have occurred after preoperative
treatment with chemoradiotherapy or after preoperative
short-course radiotherapy followed by a long interval to sur-
gery.39 However, the majority of patients in this database that
received short-course radiotherapy had surgery within an
interval of 10 days after preoperative therapy, and downsta-
ging is not observed in this group.40,41 Most importantly,
postoperative staging is the gold standard and clinical staging
using CT and MRI is rather unreliable, especially regarding
lymph node staging.18,42
Last, yp-TNM and p-TNM are grouped together for the
analyses in this study to give a global overview of the epidemi-
ology of CRC in the Netherlands. However, it should be taken
into account that differences in survival between p-TNM and
yp-TNM are not fully comparable. Bosch et al. described that
not only survival was different between p-TNM and yp-TNM
patients, but also clinical staging signiﬁcantly differed between
these patient groups making comparison difﬁcult.43
In conclusion, this study showed an increase in incidence
and an ongoing improvement in survival. This improvement
in survival is a continuum, which is partly due to evolving
cancer treatment, but also to other factors in the organization
of care for CRC patients. The increasing incidence of CRC
favors the implementation of the national screening program.
It is to be expected that further patient tailored treatment
based on better insight into tumor heterogeneity, and the
screening program, will further improve survival in the com-
ing years, but the effects should be monitored closely.
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